UNC Lineberger has launched a first-of-its-kind clinical trial aimed at improving outcomes in BRAF wildtype anaplastic thyroid cancer (ATC). Siddharth Sheth, DO, MPH, and Jeffrey Blumberg, MD, FACS, are leading the trial.| UNC Lineberger
